{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:51:57Z","timestamp":1789692717580,"version":"4.0.1"},"reference-count":29,"publisher":"Harborside Press, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The presence of variants of uncertain significance (VUS) should not influence clinical management; however, prior studies on breast cancer\u2013related health care utilization in women with VUS versus negative germline genetic test results have shown conflicting findings. This study evaluated whether receipt of a VUS influences breast cancer\u2013related health care utilization. <jats:bold>Methods:<\/jats:bold> This large study analyzed health care utilization and costs in women who underwent clinical multigene panel testing (MGPT) between 2015 and 2023 at a single commercial laboratory with \u22652 years of health insurance claims data available. Multivariable logistic regression was used to assess differences in the uptake of surgical, therapeutic, risk-reducing, and surveillance modalities, as well as the associated health care costs, between women with VUS or negative MGPT results after the return of test findings. <jats:bold>Results:<\/jats:bold> Of 50,657 eligible women (mean age, 47.7 years), most were White (66.8%), had a family history of cancer (87.0%), and had commercial insurance (71.1%). Among 22,699 patients with breast cancer, those with VUS showed no differences from those with negative results in the uptake of surgical, therapeutic, risk-reducing, and surveillance procedures or in the adjusted cost of surgical procedures after genetic testing. Among 27,958 cancer-free women, those with negative results had modestly lower mammography use (odds ratio, 0.9; 95% CI, 0.8\u20130.9) compared with those with VUS. Breast cancer screening and treatment costs were no higher for women with VUS versus negative results, but were up to 10 times higher for those with positive results. <jats:bold>Conclusions:<\/jats:bold> In a large, real-world sample of women with breast cancer and without any cancer, use of cancer treatments, surveillance, and risk-reducing measures did not differ between patients with VUS versus negative results, except for modestly higher mammography use. These findings offer reassurance that VUS results do not lead to overutilization or increased cost of health care.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7011","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:39:24Z","timestamp":1749645564000},"page":"248-254","source":"Crossref","is-referenced-by-count":4,"title":["Utilization of Cancer Screening, Prevention, and Treatment in Women With Variants of Uncertain Significance in Breast Cancer Susceptibility Genes"],"prefix":"10.6004","volume":"23","author":[{"given":"Sarah M.","family":"Nielsen","sequence":"first","affiliation":[{"name":"Labcorp (formerly Invitae Corp.), San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Russell","sequence":"additional","affiliation":[{"name":"Labcorp (formerly Invitae Corp.), San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Ellsworth","sequence":"additional","affiliation":[{"name":"Labcorp (formerly Invitae Corp.), San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S.","family":"Hughes","sequence":"additional","affiliation":[{"name":"Division of Oncologic & Endocrine Surgery, Department of Surgery, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandie","family":"Heald","sequence":"additional","affiliation":[{"name":"Former employee of Invitae Corp., San Francisco, CA"},{"name":"Exact Sciences, Madison, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Beitsch","sequence":"additional","affiliation":[{"name":"Baylor Genetics, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Moretz","sequence":"additional","affiliation":[{"name":"Former employee of Invitae Corp., San Francisco, CA"},{"name":"Dallas Surgical Group, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Pineda-Alvarez","sequence":"additional","affiliation":[{"name":"Labcorp (formerly Invitae Corp.), San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Esplin","sequence":"additional","affiliation":[{"name":"Labcorp (formerly Invitae Corp.), San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Nussbaum","sequence":"additional","affiliation":[{"name":"Former employee of Invitae Corp., San Francisco, CA"},{"name":"Division of Medical Genetics, Department of Pediatrics, University of San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia M.","family":"Facio","sequence":"additional","affiliation":[{"name":"Labcorp (formerly Invitae Corp.), San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison W.","family":"Kurian","sequence":"additional","affiliation":[{"name":"Departments of Medicine and of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"NCCN Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 2.2021","author":"Daly MB","unstructured":"Daly MB, Pal T, Berry MP,  NCCN Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 2.2021. Accessed January 28, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B2","article-title":"NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. Version 1.2020","author":"Bevers TB","unstructured":"Bevers TB, Ward JH, Ahrendt GM,  NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. Version 1.2020. Accessed January 28, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B3","series-title":"J Clin Oncol","first-page":"2080","article-title":"Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline","volume":"38","author":"Tung NM","year":"2020","unstructured":"Tung NM, Boughey JC, Pierce LJ,  Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology guideline. J Clin Oncol 2020;38:2080\u20132106."},{"key":"B4","series-title":"N Engl J Med","first-page":"523","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson M","year":"2017","unstructured":"Robson M, Im SA, Senkus E,  Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377:523\u2013533."},{"key":"B5","series-title":"N Engl J Med","first-page":"2394","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt ANJ","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B,  Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 2021;384:2394\u20132405."},{"key":"B6","series-title":"Genet Med","first-page":"405","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards S","year":"2015","unstructured":"Richards S, Aziz N, Bale S,  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405\u2013424."},{"key":"B7","series-title":"Ann Surg Oncol","first-page":"3025","article-title":"Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons","volume":"26","author":"Manahan ER","year":"2019","unstructured":"Manahan ER, Kuerer HM, Sebastian M,  Consensus guidelines on genetic testing for hereditary breast cancer from the American Society of Breast Surgeons. Ann Surg Oncol 2019;26:3025\u20133031."},{"key":"B8","series-title":"Fam Cancer","first-page":"121","article-title":"Physician interpretation of variants of uncertain significance","volume":"18","author":"Macklin SK","year":"2019","unstructured":"Macklin SK, Jackson JL, Atwal PS, Hines SL. Physician interpretation of variants of uncertain significance. Fam Cancer 2019;18:121\u2013126."},{"key":"B9","series-title":"J Clin Oncol","first-page":"2232","article-title":"Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer","volume":"35","author":"Kurian AW","year":"2017","unstructured":"Kurian AW, Li Y, Hamilton AS,  Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol 2017;35:2232\u20132239."},{"key":"B10","series-title":"Clin Genet","first-page":"523","article-title":"Genetic counselors\u2019 practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing","volume":"88","author":"Scherr CL","year":"2015","unstructured":"Scherr CL, Lindor NM, Malo TL,  Genetic counselors\u2019 practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing. Clin Genet 2015;88:523\u2013529."},{"key":"B11","series-title":"Patient Educ Couns","first-page":"1692","article-title":"The impact of communicating uncertain test results in cancer genetic counseling: a systematic mixed studies review","volume":"103","author":"Medendorp NM","year":"2020","unstructured":"Medendorp NM, van Maarschalkerweerd PEA, Murugesu L,  The impact of communicating uncertain test results in cancer genetic counseling: a systematic mixed studies review. Patient Educ Couns 2020;103:1692\u20131708."},{"key":"B12","series-title":"Ann Surg Oncol","first-page":"3060","article-title":"Expanded gene panel use for women with breast cancer: identification and intervention beyond breast cancer risk","volume":"24","author":"O\u2019Leary E","year":"2017","unstructured":"O\u2019Leary E, Iacoboni D, Holle J,  Expanded gene panel use for women with breast cancer: identification and intervention beyond breast cancer risk. Ann Surg Oncol 2017;24:3060\u20133066."},{"key":"B13","series-title":"J Clin Oncol","first-page":"453","article-title":"Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle?","volume":"37","author":"Beitsch PD","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K,  Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 2019;37:453\u2013460."},{"key":"B14","series-title":"Cancer","first-page":"1721","article-title":"A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes","volume":"123","author":"Buys SS","year":"2017","unstructured":"Buys SS, Sandbach JF, Gammon A,  A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer 2017;123:1721\u20131730."},{"key":"B15","series-title":"JAMA Netw Open","first-page":"e2339571.","article-title":"Rates and classification of variants of uncertain significance in hereditary disease genetic testing","volume":"6","author":"Chen E","year":"2023","unstructured":"Chen E, Facio FM, Aradhya KW,  Rates and classification of variants of uncertain significance in hereditary disease genetic testing. JAMA Netw Open 2023;6:e2339571."},{"key":"B16","series-title":"Ann Surg Oncol","first-page":"3067","article-title":"Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes","volume":"24","author":"Welsh JL","year":"2017","unstructured":"Welsh JL, Hoskin TL, Day CN,  Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes. Ann Surg Oncol 2017;24:3067\u20133072."},{"key":"B17","series-title":"Ann Surg Oncol","first-page":"4613","article-title":"Contralateral risk-reducing mastectomy in breast cancer patients who undergo multigene panel testing","volume":"27","author":"Murphy BL","year":"2020","unstructured":"Murphy BL, Yi M, Arun BK,  Contralateral risk-reducing mastectomy in breast cancer patients who undergo multigene panel testing. Ann Surg Oncol 2020;27:4613\u20134621."},{"key":"B18","series-title":"Ann Surg Oncol","first-page":"3389","article-title":"Clinical management of patients at risk for hereditary breast cancer with variants of uncertain significance in the era of multigene panel testing","volume":"26","author":"Chang J","year":"2019","unstructured":"Chang J, Seng S, Yoo J,  Clinical management of patients at risk for hereditary breast cancer with variants of uncertain significance in the era of multigene panel testing. Ann Surg Oncol 2019;26:3389\u20133396."},{"key":"B19","series-title":"J Am Coll Surg","first-page":"560","article-title":"Impact of multigene panel testing on surgical decision making in breast cancer patients","volume":"226","author":"Pederson HJ","year":"2018","unstructured":"Pederson HJ, Gopalakrishnan D, Noss R,  Impact of multigene panel testing on surgical decision making in breast cancer patients. J Am Coll Surg 2018;226:560\u2013565."},{"key":"B20","series-title":"JAMA Oncol","first-page":"1066","article-title":"Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer","volume":"4","author":"Kurian AW","year":"2018","unstructured":"Kurian AW, Ward KC, Hamilton AS,  Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol 2018;4:1066\u20131072."},{"key":"B21","series-title":"JAMA Oncol","first-page":"e196400.","article-title":"Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer","volume":"6","author":"Kurian AW","year":"2020","unstructured":"Kurian AW, Ward KC, Abrahamse P,  Association of germline genetic testing results with locoregional and systemic therapy in patients with breast cancer. JAMA Oncol 2020;6:e196400."},{"key":"B22","series-title":"J Comp Eff Res","first-page":"207","article-title":"Economic impact of multigene panel testing for hereditary breast and ovarian cancer","volume":"10","author":"Byfield SD","year":"2021","unstructured":"Byfield SD, Wei H, DuCharme M, Lancaster JM. Economic impact of multigene panel testing for hereditary breast and ovarian cancer. J Comp Eff Res 2021;10:207\u2013217."},{"key":"B23","series-title":"J Stat Softw","article-title":"mice: Multivariate Imputation by Chained Equations in R","volume":"45","author":"van Buuren S","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. J Stat Softw 2011;45:1\u201367."},{"key":"B24","series-title":"J Genet Couns","first-page":"1116","article-title":"Impact of panel gene testing for hereditary breast and ovarian cancer on patients","volume":"26","author":"Lumish HS","year":"2017","unstructured":"Lumish HS, Steinfeld H, Koval C,  Impact of panel gene testing for hereditary breast and ovarian cancer on patients. J Genet Couns 2017;26:1116\u20131129."},{"key":"B25","series-title":"Genet Med","first-page":"100960.","article-title":"\u201cI don\u2019t need any more unknowns hanging over my head\u201d: views of patients with cancer on variants of uncertain significance and low\/moderate risk results from genomic sequencing","volume":"25","author":"Shickh S","year":"2023","unstructured":"Shickh S, Mighton C, Clausen M,  \u201cI don\u2019t need any more unknowns hanging over my head\u201d: views of patients with cancer on variants of uncertain significance and low\/moderate risk results from genomic sequencing. Genet Med 2023;25:100960."},{"key":"B26","series-title":"Cancer","first-page":"3709","article-title":"Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes","volume":"128","author":"Makhnoon S","year":"2022","unstructured":"Makhnoon S, Chen M, Levin B,  Use of breast surveillance between women with pathogenic variants and variants of uncertain significance in breast cancer susceptibility genes. Cancer 2022;128:3709\u20133717."},{"key":"B27","series-title":"Genet Med","first-page":"896","article-title":"Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations","volume":"16","author":"Garcia C","year":"2014","unstructured":"Garcia C, Lyon L, Littell RD, Powell CB. Comparison of risk management strategies between women testing positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations. Genet Med 2014;16:896\u2013902."},{"key":"B28","series-title":"Breast","first-page":"S106","article-title":"Personalizing extent of breast cancer surgery according to molecular subtypes","volume":"22","author":"Morrow M","year":"2013","unstructured":"Morrow M. Personalizing extent of breast cancer surgery according to molecular subtypes. Breast 2013;22(Suppl 2):S106\u2013109."},{"key":"B29","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"351","article-title":"Vital signs: mammography use and association with social determinants of health and health-related social needs among women \u2013 United States, 2022","volume":"73","author":"Miller JW","year":"2024","unstructured":"Miller JW, King JA, Trivers KF,  Vital signs: mammography use and association with social determinants of health and health-related social needs among women \u2013 United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:351\u2013357."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/6\/article-p248.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/6\/article-p248.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/6\/article-p248.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T12:39:24Z","timestamp":1749645564000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/6\/article-p248.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7011","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}